Published in Arthritis Rheum on February 01, 2006
Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol (2007) 1.00
Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies. Crit Care (2014) 0.92
Giant cell arteritis: Current treatment and management. World J Clin Cases (2015) 0.84
Further support for the statins as antiinflammatory and immunomodulatory agents: comment on the review by Abeles and Pillinger and the editorial by Arnaud and Mach. Arthritis Rheum (2006) 0.77
Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis. Inflammation (2016) 0.76
Simvastatin inhibits TLR8 signaling in primary human monocytes and spontaneous TNF production from rheumatoid synovial membrane cultures. Mol Med (2015) 0.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
[Statin treatment in primary and secondary prevention--a statement]. Rev Med Suisse (2014) 2.55
Inferior vena cava parameters predict re-admission in ischaemic heart failure. Eur J Clin Invest (2014) 2.01
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2003) 1.99
Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 1.90
The specific role of chemokines in atherosclerosis. Thromb Haemost (2007) 1.62
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res (2005) 1.49
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Late cardiac tamponade after percutaneous closure of a patent foramen ovale. Eur J Echocardiogr (2005) 1.41
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. Eur J Cardiovasc Prev Rehabil (2010) 1.33
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol (2008) 1.30
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol (2008) 1.25
CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol (2009) 1.24
Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation (2003) 1.22
Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med (2005) 1.22
Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.21
A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat (2008) 1.21
Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol (2009) 1.20
Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis (2006) 1.19
Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease. ILAR J (2009) 1.16
Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal (2007) 1.16
The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost (2009) 1.14
CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost (2010) 1.13
Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev (2003) 1.12
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res (2003) 1.07
PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res (2007) 1.06
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm (2009) 1.05
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J (2011) 1.05
Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol (2009) 1.04
Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04
Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail (2011) 1.03
Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis (2009) 1.01
Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke (2010) 1.00
Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation (2012) 0.99
Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm (2008) 0.99
In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J (2009) 0.99
Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J (2012) 0.98
CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J (2011) 0.98
Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging (2012) 0.98
Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis (2009) 0.97
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2010) 0.97
Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J (2011) 0.96
The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am J Respir Crit Care Med (2011) 0.96
Inflammation in the pathophysiology of essential hypertension. J Nephrol (2010) 0.95
Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm (2013) 0.95
Role of Toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. Crit Care Med (2004) 0.94
Heat stress preconditioning and delayed myocardial protection: what is new? Cardiovasc Res (2003) 0.94
Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res (2007) 0.93
Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. PLoS One (2009) 0.93
Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord (2005) 0.93
Shear stress modulates the expression of the atheroprotective protein Cx37 in endothelial cells. J Mol Cell Cardiol (2012) 0.92
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. Am J Physiol Endocrinol Metab (2011) 0.92
Sleep deprivation, sleep apnea and cardiovascular diseases. Front Biosci (Elite Ed) (2012) 0.91
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J (2011) 0.91
Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis. Eur Respir J (2013) 0.90
Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res (2002) 0.89
Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis (2010) 0.89
Inflammation and atherosclerosis. Herz (2004) 0.89
Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab (2012) 0.88
Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol (2004) 0.88
"In vivo" imaging of atherosclerosis. Atherosclerosis (2012) 0.88
Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol (2010) 0.88
The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol (2007) 0.87
Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res (2012) 0.87
Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. J Med Genet (2011) 0.86
Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes. Hypertension (2009) 0.85
Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J (2010) 0.85
C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. J Leukoc Biol (2008) 0.85
Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath (2010) 0.85
Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm (2013) 0.85
Update on the role of cannabinoid receptors after ischemic stroke. Mediators Inflamm (2012) 0.85
The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb Haemost (2012) 0.84
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost (2014) 0.84
Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost (2013) 0.84
The vulnerable coronary plaque: update on imaging technologies. Thromb Haemost (2013) 0.84
Impact of propofol anaesthesia on cytokine expression profiles in the developing rat brain: a randomised placebo-controlled experimental in-vivo study. Eur J Anaesthesiol (2015) 0.84
An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia. J Sex Med (2013) 0.83
New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging (2008) 0.83
Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? Nat Clin Pract Nephrol (2006) 0.83
New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Rev Cardiovasc Ther (2010) 0.83
Myocardial infarction quantification with Manganese-Enhanced MRI (MEMRI) in mice using a 3T clinical scanner. NMR Biomed (2010) 0.83
Dual benefit of reduced Cx43 on atherosclerosis in LDL receptor-deficient mice. Cell Commun Adhes (2003) 0.83
Elevated E-selectin and diastolic blood pressure in diabetic children. Eur J Clin Invest (2011) 0.82
Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab (2009) 0.82
Atherosclerosis is an inflammatory disease. Semin Immunopathol (2009) 0.82